Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of kidney diseases
3.2.1.2 Increasing patient population related to urinary tract infections
3.2.1.3 Growing demand for minimally invasive procedures
3.2.1.4 Increasing adoption of advanced imaging techniques for diagnosis
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of awareness and high treatment cost
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technological landscape
3.7 Porter's analysis
3.7.1 Supplier power
3.7.2 Buyer power
3.7.3 Threat of new entrants
3.7.4 Threat of substitutes
3.7.5 Industry rivalry
3.8 PESTEL analysis
3.9 Epidemiology outlook
3.10 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Unilateral hydronephrosis
5.3 Bilateral hydronephrosis
Chapter 6 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Intrinsic
6.2.1 Acute unilateral obstructive uropathy
6.2.2 Kidney stone
6.2.3 Bladder cancer
6.2.4 Bladder stones
6.2.5 Urethral stricture
6.2.6 Pelvic organ prolapse
6.2.7 Other intrinsic indications
6.3 Extrinsic
6.3.1 Retroperitoneal fibrosis
6.3.2 Ovarian vein syndrome
6.3.3 Other extrinsic indications
Chapter 7 Market Estimates and Forecast, By Diagnosis, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Laboratory tests
7.2.1 Urinalysis
7.2.2 Complete blood count
7.2.3 Electrolyte analysis
7.2.4 Other laboratory tests
7.3 Imaging
7.3.1 Ultrasound
7.3.2 Intravenous pyelography
7.3.3 KUB X-Rays
7.3.4 CT-scan
7.3.5 Other imaging types
Chapter 8 Market Estimates and Forecast, By Treatment, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Shock wave lithotripsy
8.3 Laparoscopy
8.4 Bladder catheterization
8.5 Steroid therapy
8.6 Other treatments
Chapter 9 Market Estimates and Forecast, By Age Group, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Adult
9.3 Pediatric
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie Inc.
11.2 Amgen Inc.
11.3 The Anthem Group
11.4 F. Hoffmann-La Roche Ltd.
11.5 Nephrogenex Inc.
11.6 Novartis AG
11.7 Pfizer Inc.
11.8 Phraxis Inc.
11.9 Renal Associates P.A.
11.10 Sanofi
